| Brooks Thorson, DNP | |
|
900 E Broadway Ave, Bismarck, ND 58501-4520 | |
| (701) 290-0636 | |
| Not Available |
| Full Name | Brooks Thorson |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 900 E Broadway Ave, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396303137 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | R39200 (North Dakota) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | R39200 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi St Alexius Health | Bismarck, ND | Hospital |
| Chi St Alexius Health Dickinson | Dickinson, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Alexius Medical Center | 8426960865 | 205 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).
As electronic health records become more widely deployed, increasing amounts of health information are being collected. This data has many beneficial applications, such as research, public health, and health system planning. In a recent study, Dr. Khaled El Emam, the Canada Research Chair in Electronic Health Information at the CHEO Research Institute argues that there is a need for robust de-identification of patient data to avoid the negative impact that individual consent requirements have on studies using health record data for secondary purposes.
The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.
› Verified 6 days ago
| Entity Name | St Alexius Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868429 PECOS PAC ID: 8426960865 Enrollment ID: O20031104000146 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).
As electronic health records become more widely deployed, increasing amounts of health information are being collected. This data has many beneficial applications, such as research, public health, and health system planning. In a recent study, Dr. Khaled El Emam, the Canada Research Chair in Electronic Health Information at the CHEO Research Institute argues that there is a need for robust de-identification of patient data to avoid the negative impact that individual consent requirements have on studies using health record data for secondary purposes.
The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brooks Thorson, DNP 900 E Broadway Ave, Bismarck, ND 58501-4520 Ph: (701) 530-7500 | Brooks Thorson, DNP 900 E Broadway Ave, Bismarck, ND 58501-4520 Ph: (701) 290-0636 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).
As electronic health records become more widely deployed, increasing amounts of health information are being collected. This data has many beneficial applications, such as research, public health, and health system planning. In a recent study, Dr. Khaled El Emam, the Canada Research Chair in Electronic Health Information at the CHEO Research Institute argues that there is a need for robust de-identification of patient data to avoid the negative impact that individual consent requirements have on studies using health record data for secondary purposes.
The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.
In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue.
› Verified 6 days ago
Sarah Miller, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5422 Fax: 701-323-8645 | |
Danette Pengilly, GNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th St, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Jana Rakowski, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1040 Tacoma Ave, Bismarck, ND 58504 Phone: 701-323-7452 Fax: 701-323-6982 | |
Mrs. Christina R Gisvold, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Lee Ann June Short, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-204-1709 | |
Rebecca L Ritter, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 E Rosser Ave, Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6430 | |
Cheryle K Bitz, MSN, ARNP, GNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7300 Fax: 701-530-7319 |